HI
REGN icon

Humankind Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Humankind Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,275
Closed -$717K – 129
2025
Q3 		$717K Buy
1,275
+84
+7% +$47.5K 0.16% 69
2025
Q2 		$625K Sell
1,191
-239
-17% -$133K 0.15% 72
2025
Q1 		$907K Buy
1,430
+132
+10% +$90.8K 0.24% 59
2024
Q4 		$925K Buy
1,298
+498
+62% +$418K 0.23% 57
2024
Q3 		$841K Sell
800
-113
-12% -$126K 0.3% 54
2024
Q2 		$960K Sell
913
-61
-6% -$59.1K 0.25% 55
2024
Q1 		$937K Sell
974
-90
-8% -$85.6K 0.25% 53
2023
Q4 		$935K Sell
1,064
-4
-0.4% -$3.29K 0.28% 51
2023
Q3 		$879K Sell
1,068
-72
-6% -$56.6K 0.37% 40
2023
Q2 		$819K Buy
1,140
+250
+28% +$193K 0.32% 45
2023
Q1 		$731K Sell
890
-15
-2% -$11.3K 0.3% 53
2022
Q4 		$653K Sell
905
-164
-15% -$121K 0.28% 58
2022
Q3 		$736K Buy
1,069
+225
+27% +$142K 0.35% 43
2022
Q2 		$499K Buy
844
+145
+21% +$94.3K 0.24% 62
2022
Q1 		$488K Buy
699
+59
+9% +$37.3K 0.2% 66
2021
Q4 		$404K Buy
640
+76
+13% +$46.7K 0.51% 63
2021
Q3 		$341K Sell
564
-12
-2% -$7.45K 0.52% 63
2021
Q2 		$322K Buy
+576
New +$292K 0.57% 55

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Humankind Investments's REGN Position: Q4 2025 in Review

Humankind Investments sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 1,275 shares — an estimated $717K sold.

Humankind Investments first reported a position in REGN in Q2 2021 and held it in 18 quarters. The position peaked at $960K in Q2 2024. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Humankind Investments reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Humankind Investments sold 1,275 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $717K.
  • Humankind Investments first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 18 quarters.
  • Humankind Investments's Regeneron Pharmaceuticals position peaked at $960K in Q2 2024.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Humankind Investments's 13F filing for Q4 2025, filed 17 Feb 2026.